Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.33
RHHBY's Cash-to-Debt is ranked lower than
78% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. RHHBY: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
RHHBY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.26  Med: 0.45 Max: 5.08
Current: 0.33
0.26
5.08
Equity-to-Asset 0.32
RHHBY's Equity-to-Asset is ranked lower than
87% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. RHHBY: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
RHHBY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.27 Max: 0.59
Current: 0.32
0.09
0.59
Debt-to-Equity 0.93
RHHBY's Debt-to-Equity is ranked lower than
83% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. RHHBY: 0.93 )
Ranked among companies with meaningful Debt-to-Equity only.
RHHBY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09  Med: 1.1 Max: 15.36
Current: 0.93
0.09
15.36
Debt-to-EBITDA 1.20
RHHBY's Debt-to-EBITDA is ranked higher than
61% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. RHHBY: 1.20 )
Ranked among companies with meaningful Debt-to-EBITDA only.
RHHBY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.24  Med: 1.45 Max: 2.83
Current: 1.2
0.24
2.83
Interest Coverage 21.89
RHHBY's Interest Coverage is ranked lower than
63% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. RHHBY: 21.89 )
Ranked among companies with meaningful Interest Coverage only.
RHHBY' s Interest Coverage Range Over the Past 10 Years
Min: 5.94  Med: 12.43 Max: 65.07
Current: 21.89
5.94
65.07
Piotroski F-Score: 9
Altman Z-Score: 3.57
Beneish M-Score: -2.75
WACC vs ROIC
5.04%
26.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 26.44
RHHBY's Operating Margin % is ranked higher than
90% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. RHHBY: 26.44 )
Ranked among companies with meaningful Operating Margin % only.
RHHBY' s Operating Margin % Range Over the Past 10 Years
Min: 25.03  Med: 28.89 Max: 33.69
Current: 26.44
25.03
33.69
Net Margin % 18.64
RHHBY's Net Margin % is ranked higher than
84% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. RHHBY: 18.64 )
Ranked among companies with meaningful Net Margin % only.
RHHBY' s Net Margin % Range Over the Past 10 Years
Min: 15.87  Med: 18.83 Max: 22.97
Current: 18.64
15.87
22.97
ROE % 44.53
RHHBY's ROE % is ranked higher than
97% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. RHHBY: 44.53 )
Ranked among companies with meaningful ROE % only.
RHHBY' s ROE % Range Over the Past 10 Years
Min: 19.94  Med: 45.85 Max: 102.95
Current: 44.53
19.94
102.95
ROA % 13.01
RHHBY's ROA % is ranked higher than
84% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. RHHBY: 13.01 )
Ranked among companies with meaningful ROA % only.
RHHBY' s ROA % Range Over the Past 10 Years
Min: 10.33  Med: 12.78 Max: 17.58
Current: 13.01
10.33
17.58
ROC (Joel Greenblatt) % 59.29
RHHBY's ROC (Joel Greenblatt) % is ranked higher than
90% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. RHHBY: 59.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RHHBY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 52.39  Med: 65.31 Max: 84.52
Current: 59.29
52.39
84.52
3-Year Revenue Growth Rate 1.40
RHHBY's 3-Year Revenue Growth Rate is ranked lower than
65% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. RHHBY: 1.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RHHBY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.5  Med: 2.9 Max: 15.5
Current: 1.4
-3.5
15.5
3-Year EBITDA Growth Rate -2.20
RHHBY's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. RHHBY: -2.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RHHBY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -46.3  Med: 0.7 Max: 104.7
Current: -2.2
-46.3
104.7
3-Year EPS without NRI Growth Rate -4.90
RHHBY's 3-Year EPS without NRI Growth Rate is ranked lower than
69% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. RHHBY: -4.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RHHBY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.4  Med: 1 Max: 36.2
Current: -4.9
-29.4
36.2
GuruFocus has detected 5 Warning Signs with Roche Holding AG RHHBY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RHHBY's 30-Y Financials

Financials (Next Earnings Date: 2018-02-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

RHHBY Guru Trades in Q4 2016

Mairs and Power 4,982,597 sh (+7.28%)
Ken Fisher 14,946,458 sh (-1.19%)
» More
Q1 2017

RHHBY Guru Trades in Q1 2017

Mairs and Power 5,067,407 sh (+1.70%)
Ken Fisher 15,104,940 sh (+1.06%)
» More
Q2 2017

RHHBY Guru Trades in Q2 2017

Mairs and Power 5,225,487 sh (+3.12%)
Ken Fisher 11,875,382 sh (-21.38%)
» More
Q3 2017

RHHBY Guru Trades in Q3 2017

Ken Fisher 15,992,640 sh (+34.67%)
Mairs and Power 5,381,813 sh (+2.99%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 Add 34.67%0.2%$30.96 - $32.27 $ 29.10-8%15,992,640
Ken Fisher 2017-06-30 Reduce -21.38%0.17%$31.6 - $34.43 $ 29.10-11%11,875,382
Ken Fisher 2017-03-31 Add 1.06%0.01%$28.94 - $32.42 $ 29.10-5%15,104,940
Ken Fisher 2016-12-31 Reduce -1.19%0.01%$27.08 - $30.96 $ 29.101%14,946,458
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:XSWX:NOVN, NYSE:PFE, NYSE:MRK, NYSE:ABBV, XPAR:SAN, XTER:BAYN, NYSE:BMY, NYSE:LLY, LSE:GSK, LSE:AZN, TSE:4503, TSE:4519, TSE:4578, NYSE:JNJ, TSE:4568, TSE:4528, HKSE:01093, TSE:4151, MIL:REC, BOM:500087 » details
Traded in other countries:RHO5.Germany, ROG N.Mexico, RO.Switzerland, 0QOK.UK,
Headquarter Location:Switzerland
Roche Holding AG is a pharmaceutical and diagnostic company. It specializes in medicines for oncology, virology, inflammation, metabolism, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology.

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for more than 60% of pharmaceutical sales, and professional diagnostics for more than half of diagnostic-related sales.

Top Ranked Articles about Roche Holding AG

Roche launches DISCOVERY Teal HRP chromogen detection kit to advance tissue-based cancer research
Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for treatment with Roche's ALECENSA (alectinib)
Roche to initiate testing for Babesia parasite at U.S. Blood Centers under FDA Investigational New Drug Application protocol
Roche gains CE label expansion for PD-L1 testing in lung and bladder cancers in markets where TECENTRIQ is approved
3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs Diabetes accounts for nearly 10% of US health care spending
Total U.S. health care spending in 2015 was an astronomical $3.2 trillion. That is 16% of the entire national debt. As much as we blame the prices of new drugs for this gargantuan sum, one of the biggest chunks of it comes from diabetes, a disease whose treatment has not changed all that much since 1922. According to the American Diabetes Association, diabetes accounts for $322 billion in total U.S. health care spending as of 2016. Read more...
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Roche Holding AG. (RHHBY) and Lead Plaintiff Deadline: August 7, 2017
AUGUST 7 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
6-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm
Roche to showcase power of connected lab at AACC 2017 Clinical Lab Expo

Ratios

vs
industry
vs
history
PE Ratio 20.72
RHHBY's PE Ratio is ranked higher than
60% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.41 vs. RHHBY: 20.72 )
Ranked among companies with meaningful PE Ratio only.
RHHBY' s PE Ratio Range Over the Past 10 Years
Min: 13.05  Med: 19.98 Max: 29.42
Current: 20.72
13.05
29.42
Forward PE Ratio 14.22
RHHBY's Forward PE Ratio is ranked higher than
65% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.53 vs. RHHBY: 14.22 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 20.72
RHHBY's PE Ratio without NRI is ranked higher than
62% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.56 vs. RHHBY: 20.72 )
Ranked among companies with meaningful PE Ratio without NRI only.
RHHBY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.05  Med: 19.98 Max: 29.2
Current: 20.72
13.05
29.2
Price-to-Owner-Earnings 15.42
RHHBY's Price-to-Owner-Earnings is ranked higher than
78% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.43 vs. RHHBY: 15.42 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
RHHBY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.42  Med: 15.4 Max: 23.23
Current: 15.42
9.42
23.23
PB Ratio 8.73
RHHBY's PB Ratio is ranked lower than
89% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. RHHBY: 8.73 )
Ranked among companies with meaningful PB Ratio only.
RHHBY' s PB Ratio Range Over the Past 10 Years
Min: 2.59  Med: 11.17 Max: 22.21
Current: 8.73
2.59
22.21
PS Ratio 3.97
RHHBY's PS Ratio is ranked lower than
61% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. RHHBY: 3.97 )
Ranked among companies with meaningful PS Ratio only.
RHHBY' s PS Ratio Range Over the Past 10 Years
Min: 2.38  Med: 4.11 Max: 5.46
Current: 3.97
2.38
5.46
Price-to-Free-Cash-Flow 20.05
RHHBY's Price-to-Free-Cash-Flow is ranked higher than
57% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.72 vs. RHHBY: 20.05 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
RHHBY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.6  Med: 17.42 Max: 37.16
Current: 20.05
8.6
37.16
Price-to-Operating-Cash-Flow 13.37
RHHBY's Price-to-Operating-Cash-Flow is ranked higher than
63% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. RHHBY: 13.37 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RHHBY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 13.6 Max: 22.22
Current: 13.37
6.98
22.22
EV-to-EBIT 15.72
RHHBY's EV-to-EBIT is ranked higher than
59% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. RHHBY: 15.72 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHBY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 14.2 Max: 19.8
Current: 15.72
7.5
19.8
EV-to-EBITDA 12.10
RHHBY's EV-to-EBITDA is ranked higher than
63% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. RHHBY: 12.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
RHHBY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3  Med: 12 Max: 15.7
Current: 12.1
6.3
15.7
EV-to-Revenue 4.11
RHHBY's EV-to-Revenue is ranked lower than
61% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. RHHBY: 4.11 )
Ranked among companies with meaningful EV-to-Revenue only.
RHHBY' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.2  Med: 4.3 Max: 5.3
Current: 4.11
2.2
5.3
PEG Ratio 19.09
RHHBY's PEG Ratio is ranked lower than
95% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.89 vs. RHHBY: 19.09 )
Ranked among companies with meaningful PEG Ratio only.
RHHBY' s PEG Ratio Range Over the Past 10 Years
Min: 0.23  Med: 3.43 Max: 23.21
Current: 19.09
0.23
23.21
Shiller PE Ratio 20.29
RHHBY's Shiller PE Ratio is ranked higher than
78% of the 204 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.18 vs. RHHBY: 20.29 )
Ranked among companies with meaningful Shiller PE Ratio only.
RHHBY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.32  Med: 22.51 Max: 26.42
Current: 20.29
18.32
26.42
Current Ratio 1.29
RHHBY's Current Ratio is ranked lower than
79% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. RHHBY: 1.29 )
Ranked among companies with meaningful Current Ratio only.
RHHBY' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 1.79 Max: 3.75
Current: 1.29
1.09
3.75
Quick Ratio 0.92
RHHBY's Quick Ratio is ranked lower than
79% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. RHHBY: 0.92 )
Ranked among companies with meaningful Quick Ratio only.
RHHBY' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.49 Max: 3.22
Current: 0.92
0.75
3.22
Days Inventory 167.32
RHHBY's Days Inventory is ranked lower than
74% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. RHHBY: 167.32 )
Ranked among companies with meaningful Days Inventory only.
RHHBY' s Days Inventory Range Over the Past 10 Years
Min: 143.33  Med: 159.24 Max: 186.16
Current: 167.32
143.33
186.16
Days Sales Outstanding 64.70
RHHBY's Days Sales Outstanding is ranked higher than
58% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. RHHBY: 64.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHBY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.14  Med: 73.32 Max: 84.09
Current: 64.7
63.14
84.09
Days Payable 56.60
RHHBY's Days Payable is ranked lower than
60% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 68.69 vs. RHHBY: 56.60 )
Ranked among companies with meaningful Days Payable only.
RHHBY' s Days Payable Range Over the Past 10 Years
Min: 49.43  Med: 60.53 Max: 78.64
Current: 56.6
49.43
78.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.53
RHHBY's Dividend Yield % is ranked higher than
85% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. RHHBY: 3.53 )
Ranked among companies with meaningful Dividend Yield % only.
RHHBY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.06  Med: 2.98 Max: 4.55
Current: 3.53
1.06
4.55
Dividend Payout Ratio 0.73
RHHBY's Dividend Payout Ratio is ranked lower than
83% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RHHBY: 0.73 )
Ranked among companies with meaningful Dividend Payout Ratio only.
RHHBY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.6 Max: 0.78
Current: 0.73
0.31
0.78
3-Year Dividend Growth Rate 3.30
RHHBY's 3-Year Dividend Growth Rate is ranked lower than
58% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. RHHBY: 3.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
RHHBY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.3  Med: 13 Max: 27.3
Current: 3.3
3.3
27.3
Forward Dividend Yield % 3.53
RHHBY's Forward Dividend Yield % is ranked higher than
85% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. RHHBY: 3.53 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.45
RHHBY's 5-Year Yield-on-Cost % is ranked higher than
82% of the 849 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. RHHBY: 4.45 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
RHHBY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.33  Med: 3.73 Max: 5.7
Current: 4.45
1.33
5.7
3-Year Average Share Buyback Ratio -0.10
RHHBY's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. RHHBY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RHHBY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.05 Max: 0.9
Current: -0.1
-0.8
0.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 75.82
RHHBY's Price-to-Tangible-Book is ranked lower than
98% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. RHHBY: 75.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RHHBY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.06  Med: 7.05 Max: 347.95
Current: 75.82
0.06
347.95
Price-to-Graham-Number 8.36
RHHBY's Price-to-Graham-Number is ranked lower than
96% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.97 vs. RHHBY: 8.36 )
Ranked among companies with meaningful Price-to-Graham-Number only.
RHHBY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.92  Med: 4.67 Max: 18.18
Current: 8.36
1.92
18.18
Earnings Yield (Greenblatt) % 6.36
RHHBY's Earnings Yield (Greenblatt) % is ranked higher than
72% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. RHHBY: 6.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RHHBY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5  Med: 7 Max: 13.4
Current: 6.36
5
13.4
Forward Rate of Return (Yacktman) % 6.88
RHHBY's Forward Rate of Return (Yacktman) % is ranked lower than
56% of the 397 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.07 vs. RHHBY: 6.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RHHBY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.4  Med: 8.7 Max: 63.3
Current: 6.88
3.4
63.3

More Statistics

Revenue (TTM) (Mil) $52,279.75
EPS (TTM) $ 1.42
Beta0.49
Short Percentage of Float0.00%
52-Week Range $25.25 - 36.82
Shares Outstanding (Mil)6,826.38 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 54,622 57,246 61,610
EPS ($) 1.97 2.07 2.22
EPS without NRI ($) 1.97 2.07 2.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.60%
Dividends per Share ($) 1.05 1.10 1.19

Piotroski F-Score Details

Piotroski F-Score: 99
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}